Ipamorelin 10MG

Ipamorelin 10MG

$93.00

Ipamorelin is a pentapeptide that stimulates growth hormone release without affecting other hormones. It supports muscle growth by boosting IGF-1 production. Ipamorelin’s operational mechanics enables the peptide to stimulate the production of pituitary gland-based expression of secretions related to growth amongst animal test subjects. At the same time, the presence of the peptide has been shown to inhibit the production of a secretion known as somatostatin.

110 in stock (can be backordered)

Quantity Discount / Amount Price
3 4% $89.28
5 7% $86.49
10 11% $82.77
Summary
Ipamorelin 10MG$93.00
$93.00

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

Ipamorelin is a synthetic pentapeptide that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R) and functions as a growth hormone secretagogue. It was developed as a potent stimulator of growth hormone (GH) release with high specificity and selectivity. Ipamorelin mimics the action of ghrelin, the endogenous ligand for GHS-R, leading to increased GH secretion from the pituitary gland without significantly affecting other hormones like ACTH or cortisol.

Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2

Molecular Formula: C38H49N9O5

Molecular Weight: 711.868 g/mol

CAS Number: 170851-70-4

  1. Growth Hormone Stimulation: Ipamorelin has demonstrated potent GH-releasing effects both in vitro and in vivo. Studies in rats showed that ipamorelin stimulates GH release with potency and efficacy comparable to GHRP-6, a well-known GH secretagogue.
  2. Selectivity: Unlike other GH secretagogues, ipamorelin exhibits high selectivity for GH release. It does not significantly affect the release of other pituitary hormones such as ACTH, cortisol, prolactin, FSH, LH, or TSH, making it unique among GH secretagogues.
  3. Body Composition Effects: In animal studies, ipamorelin has been shown to increase body weight gain, particularly in the first 1-2 weeks of treatment. It also increased total body fat percentages and relative fat pad weights compared to controls.
  4. Gastrointestinal Motility: Ipamorelin has been investigated for its potential to improve gastric motility in the setting of postoperative ileus. While animal studies showed promising results, human clinical trials have not demonstrated significant efficacy.
  5. Safety Profile: Ipamorelin has shown a favorable safety profile in studies, with adverse effects being rare and similar to those reported with other GH secretagogues.

  1. Clinical Efficacy: Further human studies are needed to fully evaluate ipamorelin's effects on growth hormone levels, body composition, and potential therapeutic applications.
  2. Long-term Safety: Extended studies are required to assess the long-term safety profile of ipamorelin, particularly in diverse patient populations.
  3. Therapeutic Applications: Research into ipamorelin's potential benefits in conditions such as growth hormone deficiency, sarcopenia, and age-related decline in GH secretion is warranted.
  4. Combination Therapies: Exploring potential synergistic effects of ipamorelin with other therapeutic agents could open new avenues for treatment in various medical fields.
  5. Mechanism of Action: Additional studies to fully elucidate the molecular mechanisms by which ipamorelin exerts its effects across different tissue types are needed.

  1. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/9849822/
  2. Sinha, D.K., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149-S159. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108996/
  3. Beck, D.E., et al. (2014). Efficacy of Ipamorelin, a ghrelin mimetic, on postoperative ileus in bowel resection patients. Journal of Gastrointestinal Surgery, 18(6), 1063-1071. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/24700230/
  4. Gobburu, J.V., et al. (2011). Pharmacokinetics/pharmacodynamics of ipamorelin, a novel growth hormone secretagogue, in healthy volunteers. Journal of Clinical Pharmacology, 51(3), 311-320. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/20484613/
  5. Stier, H., et al. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15. [Online].
    Available: https://jofem.org/index.php/jofem/article/view/157/194
Ipamorelin represents a promising avenue for selective growth hormone stimulation with potential applications in various medical fields. As with all peptide therapies, it is important to use ipamorelin under medical supervision, and its potential benefits and risks require ongoing evaluation through long-term clinical use and further research.